Day One Biopharmaceutical... (DAWN)
Bid | 6.08 |
Market Cap | 635.54M |
Revenue (ttm) | 161.92M |
Net Income (ttm) | -69.08M |
EPS (ttm) | -0.65 |
PE Ratio (ttm) | -9.65 |
Forward PE | -7.47 |
Analyst | Buy |
Ask | 6.87 |
Volume | 818,688 |
Avg. Volume (20D) | 1,560,080.2 |
Open | 6.21 |
Previous Close | 6.27 |
Day's Range | 6.15 - 6.32 |
52-Week Range | 6.08 - 16.76 |
Beta | -1.24 |
About DAWN
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for DAWN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
2 weeks ago · seekingalpha.com
Day One Biopharmaceuticals, Inc. (DAWN) Q1 2025 Earnings Call TranscriptDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Joey Perrone - Senior Vice President, Finance & Investor Relations Jeremy B...

1 month ago · https://www.marketscreener.com
Investing in the $532B Oncology Boom: Key Stocks Shaping the Future of Cancer TreatmentThe global oncology drug market, valued at over $200 billion today, is on pace to reach $532 billion by 2031-a growth story driven not just by rising demand but by genuine innovation. After years of i...

1 month ago · seekingalpha.com
Day One Biopharmaceuticals Pullback Is A Potential Buying OpportunityDay One Biopharmaceuticals' Ojemda launched in Q2'24 and generated $57.2M in net product revenues in 2024. Despite reporting continued sales growth so far, DAWN's stock is near 52-week lows, perhaps i...

2 months ago · seekingalpha.com
Day One Biopharmaceuticals, Inc. (DAWN) Q4 2024 Earnings Call TranscriptDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Joey Perrone - SVP, Finance and IR Jeremy Bender - CEO Lauren Merendi...